MGd is a radiation and chemotherapy sensitizing agent with a novel mechanism of action. Close The biological and chemical explanation for how a drug works. Programmed cell death or suicide that results from interrupted cellular functions. A addition of negative charge to oxygen that triggers specific chemical reactions to take place within the cell.
Mechanism of Action
Apoptosis
Redox-dependent pathways

Patents
Motexafin gadolinium (MGd) has an extensive portfolio of issued patents and pending non-provisional patent applications claiming composition of matter, synthesis/manufacturing, formulation, and methods of use. These are expected to provide commercial protection for MGd to at least 2025 in the US, UK and other international markets, which are subject to patent term extensions.
Partnering
Pharmacyclics will be seeking strategic pharma biotech partnership(s) to further develop and commercialize MGd.